. Although there was a tendency for immediate hypersensitivity to allergen to return late after discontinuation, there was sustained reduction in the late skin response and associated CD3+ T cell infiltration and interleukin-4 messenger RNA expression. Conclusions. Immunotherapy for grass pollen allergy for three to four years induces prolonged clinical remission accompanied by a persistent alteration in immunologic reactivity. (N Engl J Med 1999;341:468-75) 
Allergen immunotherapy for grass pollen hay
despite controlled studies documenting efficacy for pollen hay fever, 2 the occurrence of serious side effects fever: indications and efficacy Although allergen immunotherapy was first described (and deaths) led to virtual proscription of this treatment in the UK by the Committee on Safety of Medicines in nearly 100 years ago, 1 its use in clinical practice in the UK has a chequered history and it remains regarded by 1986. 3 However, the science of allergy has moved on considerably to the point where many allergen proteins many as a fringe treatment of dubious benefit. This is in sharp contrast to practice in continental Europe and have been cloned and characterised at a molecular level, crystal structures solved for some, and IgE and T cell the USA, so who is right? Initially allergen immunotherapy, which entails subcutaneous injection of inreactive epitopes carefully mapped. 4 5 This scientific advance holds the prospect of engineered allergens with creasing doses of allergen extract to achieve a standardised monthly maintenance dose, involved givlow IgE binding and the use of peptide fragments of allergen to reduce the potential for anaphylaxis. Does ing crude allergen extracts and was given widely with varied protocols and often minimal supervision. The the evidence from trials of current immunotherapy suggest that such efforts are justified? potential side effect of injecting allergen into any specifically IgE sensitised individual is anaphylaxis and,
The introductory article by Durham and co-workers is one of a series following a carefully monitored cohort However, trial results are variable, and this may reflect the patient selection and the quality of the allergen of patients with severe grass pollen hay fever since the late 1980s in work that sets standards of excellence in extracts used. The heterogeneity of perennial rhinitis and difficulty in firmly attributing symptoms to a parstudy design and has results in a series of seminal clinical and mechanistic reports. [7] [8] [9] [10] Initially they reported a one ticular allergen make patient selection more difficult in perennial disease. In addition, chronic allergen exyear treatment period using a modern alum absorbed, biologically standardised grass pollen extract to treat posure, as for house dust mite, may limit the total dose of allergen that can be given by AII. It is estimated that patients with severe hay fever symptoms uncontrolled by conventional anti-allergic treatment (such as topical 5-20 g of major allergen is required for efficacy, 21 although the relative quantities of different allergen nasal and intermittent systemic steroids, antihistamines, and cromoglycate eye drops). 7 This work confirmed the proteins (such as Der p 1-10 in house dust mite or D pteronyssinus extracts) in each extract can vary. At present dramatic clinical efficacy reported by Frankland and others in previous studies.
2 There were only two systemic in the UK AII with allergens other than bee and wasp venom or grass pollen should be as part of controlled reactions to treatment, both of which occurred within the first 20 minutes after injection and were rapidly studies to define more clearly which patients would benefit from this treatment. reversed by adrenaline. Nonetheless, this emphasises that allergen immunotherapy (AII) should be given in hospital by trained staff familiar with this treatment, with immediate resuscitation facilities to hand. 11 Seasonal Immunotherapy for asthma Although meta-analysis of a number of studies has rhinitis is often seen as a minor irritant by physicians and many would perhaps question the need for AII for suggested benefit from immunotherapy for asthma, the responses detected are variable and less useful for perhay fever. In fact, the major quality of life (QOL) impact and health economic costs of seasonal rhinitis, which ennial asthma than seasonal asthma related, for example, to grass pollen allergy. 22 23 Thus, immunotherapy for scores higher than angina on QOL questionnaires, have been documented 12 as have significant improvements in ragweed allergy achieved a significant but small improvement in lung function (peak flow rates), and an QOL scores after grass pollen immunotherapy. 13 Patient preference assessment showed a clear preference for accompanying commentary suggested that better treatment responses could be achieved with inhaled cortico-AII. White et al 14 recently surveyed control of seasonal rhinitis in a large primary care study. Even when 142 steroids or other conventional therapy for asthma. 24 25 Although widely practised in other countries, impatients used optimal pharmacotherapy, only 38% reported good control of their hay fever symptoms. If only munotherapy for asthma is currently contraindicated in the UK. 11 21 However, seasonal asthma due to grass 10% of these patients were suitable for grass pollen immunotherapy, it would suggest that 5000-10 000 pollen allergy is not a contraindication for AII for severe hay fever, and grass pollen immunotherapy can reduce patients might benefit from such treatment in the UK, far beyond the capacity of current allergy services.
non-specific bronchial responsiveness and seasonal asthma symptoms. 13 There is a clear need for comPatient selection is vital for immunotherapy. Ideally, patients should have symptoms exclusively or largely parative studies of AII and other treatments for asthma, and to assess patient preference for treatment. Another attributable to one allergen (the specificity of allergens means that, for example, grass pollen immunotherapy possibility that needs exploration is whether AII might modify the course of disease in asthma, rather than will not control symptoms from tree pollen), not have chronic asthma (a contraindication in the UK but not keeping inflammation under control (see below). the international guidelines), and not have other significant medical conditions that might interfere with immunotherapy, or that immunotherapy might affect -
Other modes of immunotherapy
In an attempt to reduce the risk of anaphylaxis from for example, blocker treatment precludes resuscitation from anaphylaxis with adrenaline and is an absolute conventional AII (although this is less than one in 1000 injections in the allergy clinic setting 11 ), a number of contraindication, and AII should be used with caution in autoimmune disease. 11 Even given these careful selection alternative routes of administration or modification of allergens has been explored. Nasal immunotherapy incriteria, it is likely that a large number of patients could benefit from grass pollen immunotherapy. At present volves giving doses of nasal allergen before the pollen season and, although it appears to alleviate seasonal there are no published studies of the health economics of AII; this is a clear priority.
symptoms, the side effects are such that benefit is questionable. 26 Oral immunotherapy has been disappointing, but sublingual dosing has been reported to confer symptomatic relief in randomised controlled Immunotherapy for other allergens The longest established indication for AII in the UK is studies. 27 These modes of administration have not been compared with more conventional subcutaneous inanaphylaxis to bee or wasp venom. This treatment is indicated in patients with a clear history of anaphylaxis jection. AII is thought to act by altering T cell reactivity (see (generalised systemic reactions including laryngeal oedema, asthma, collapse) or generalised urticaria if below), but the potential for side effects results from binding to allergen specific IgE. A number of approaches there is a high probability of re-sting -for example, bee keepers. The presence of venom specific IgE can be have thus been taken to preserve T cell epitopes but reduce IgE binding. Allergoids are chemically altered confirmed on skin prick testing or with radioallergosorbent testing of serum (RAST). Trials involving allergen proteins which seem to be active in controlling symptoms 28 but have not yet been shown convincingly to sting challenge suggest that this treatment reduces the risk of anaphylaxis upon re-sting from around 50% to reduce side effects from treatment. Since many allergens have been cloned and IgE binding epitopes defined, it less than 5%. 15 Double blind placebo controlled studies have also is feasible to engineer recombinant molecules that lack or have reduced IgE binding. This has been done for shown efficacy for AII for other allergens including birch pollen, 16 cat, 17 18 and house dust mite rhinitis. 19 20 house dust mite 29 and birch pollen proteins 30 and trials of group.bmj.com on April 14, 2017 -Published by http://thorax.bmj.com/ Downloaded from these vaccines are currently underway. Allergen proteins optimisation of delivery, vaccines, and potential adjuvants for this therapy. are processed by antigen presenting cells and complexed with MHC molecules to be presented to T cell receptors. Another approach to treatment is to generate peptides from allergen molecules that do not bind IgE, but do How long does allergen immunotherapy work for? act on T cells. This approach was supported by animal models 31 32 and proof of concept was provided by studies The study by Durham et al suggests that treatment for 3-4 years with grass pollen AII affords clinical benefit using peptides derived from the major cat allergen (Fel d 1) . 33 These vaccines did show some symptomatic for at least a further three years. This is in line with other studies of AII, both of house dust mite and benefit, but at the expense of delayed asthmatic reactions and some early responses due to residual IgE binding.
venom extracts. 43 44 Other studies suggest that one year of treatment is not enough and that symptoms may A potential problem with the peptide approach is the restriction by MHC haplotype which means that differrecur within 2-3 years, and recent studies of venom immunotherapy suggest that 5 years of treatment is ent patients have different MHC molecules and thus recognise different peptide fragments of the allergen. 34 superior to 3 years. 44 45 Most allergists treat for 3-5 years. The immunological changes described by Durham et Immunological models in animals suggest that tolerance may extend across different parts of the molecule. Trials al are in keeping with the sustained clinical benefit they observed, though it is of note that reactivity may begin of this approach are currently underway.
to return by three years, so the longer term effects will need to be established. This treatment is generally given to young adults, and duration of benefit needs to be How does allergen immunotherapy work? The current understanding of allergic disease is that it balanced against costs and the natural history of the disease, though spontaneous improvement of severe hay results from a Th2 T cell response driving both IgE synthesis and chronic eosinophilic inflammation. 35 It fever over time is unusual, particularly in patients whose rhinitis developed in adulthood and who have had was suggested that AII induces blocking IgG 4 antibodies that block IgE interaction with allergen. 36 However, symptoms for many years. 39 There is and others have suggested that allergen sensitisation occurs early in childhood. 47 A number of genes related much interest in this immunoregulatory cytokine which can inhibit both Th1 and Th2 proliferation and cytokine to atopy and atopic disease have been defined, and risk factors for the development of atopy are well described. 48 synthesis. 40 Regulatory T cells producing IL-10 have been described, termed Tr1, and it is possible that these If AII could modify the T cell response to allergen, it might offer the prospect of prevention of allergic cells are induced by immunotherapy. 41 More recently it has been shown in mice that the T cell marker CD25 sensitisation. Indeed, two studies of AII in children suggest that this is the case. 49 50 Clearly, further work in (the chain of the IL-2 receptor), which is generally used as a marker of T cell activation, defines a subthis exciting area is required. population of regulatory T cells. 42 In this context it is of interest that Durham et al have previously described increased numbers of CD25+ cells in allergen induced Conclusion There is now clear evidence of clinical benefit from late cutaneous reactions following AII. 8 Defining the immunological mechanisms of AII should allow allergen immunotherapy for selected patients with severe LEARNING POINTS * Allergen injection immunotherapy (AII) is effective for grass pollen hay fever not responding to conventional medical therapy and can result in a 50% reduction in symptoms, an 80% reduction in treatment requirement, and improved quality of life scores. * The clinical response persists for at least three years after a three year course of grass pollen AII. * Allergen immunotherapy for hay fever should only be given by experienced hospital allergy clinics.
